Target intelligence / Profile preview

Multidrug resistance protein 1 (ABCB1)

Target
ABCB1
Molecular classification
Transporter
01

Overview

Multidrug resistance protein 1 (ABCB1), also widely known as P-glycoprotein 1 (P-gp), is a well-characterized ATP-dependent efflux transporter belonging to the ATP-binding cassette (ABC) transporter superfamily. It is primarily expressed in apical membranes of epithelial cells in barrier and excretory organs, such as the blood-brain barrier, small intestine, liver, and kidneys, where it plays a crucial protective role by pumping xenobiotics and toxic substances out of cells and back into the bloodstream or excretory pathways. In oncology, the overexpression of ABCB1 in cancer cells is a major mechanism of multidrug resistance, as it actively extrudes a wide range of structurally diverse chemotherapeutic agents, including taxanes, anthracyclines, and vinca alkaloids, thereby reducing their therapeutic efficacy. Consequently, ABCB1 has been a major target for the development of reversal agents (inhibitors) to restore chemosensitivity, though clinical success has been limited by systemic toxicities and complex drug-drug interactions. Additionally, genetic variations or mutations in the ABCB1 gene can significantly alter drug pharmacokinetics, leading to severe drug sensitivities and toxicities, particularly in the central nervous system.

Other names
P-glycoprotein 1P-gpMDR1ATP-binding cassette sub-family B member 1ATP-dependent translocase ABCB1CD243PGY1
02

Mechanism of action

Drugs targeting ABCB1 typically act as inhibitors or modulators to block the efflux of chemotherapeutic agents, thereby reversing multidrug resistance and increasing intracellular drug accumulation. Alternatively, many drugs are substrates of ABCB1, and their pharmacokinetics, systemic clearance, and tissue distribution (such as brain penetration) are determined by their active extrusion by this transporter.

03

Biological functions

Xenobiotic transportLipid transportOther
04

Disease associations

CancerOther
05

Safety considerations

Severe drug-drug interactionsNeurotoxicity due to increased blood-brain barrier permeabilityIncreased systemic toxicity of co-administered chemotherapeuticsAltered pharmacokinetics of narrow therapeutic index drugs (e.g., digoxin)Genetic polymorphism-induced variability in drug sensitivity
06

Interacting drugs

15 more in the full profile.

07

Biomarkers

ABCB1 gene expressionP-glycoprotein expressionABCB1 C3435T polymorphismABCB1-1Δ mutationRhodamine 123 efflux activity

Beyond the preview

Go deeper on Multidrug resistance protein 1 (ABCB1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Multidrug resistance protein 1 (ABCB1).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call